Microbial Genomics Biomedical Core

微生物基因组学生物医学核心（MGBC）：项目总结/摘要 哥伦比亚大学奥布莱恩泌尿学研究中心的使命是确定遗传因素， 先天性畸形，如膀胱输尿管反流，使个体易患尿路感染 (UTI)并探索宿主细菌的代谢过程，如血红素途径，使或防止 感染UTI是最常见的感染之一，每年影响全球1.5亿人。在 支持哥伦比亚奥布莱恩泌尿学研究中心的目标，微生物基因组学和生物医学 核心（MGBC）将为生物库，扩展细菌培养，微生物基因组学提供高质量的服务 （微生物组分析、比较基因组学）、微生物遗传学、研究设计咨询和推广 用于对尿路感染的发病机理进行新的研究。MGBC将使哥伦比亚奥布莱恩 中心研究人员可以获得专门的基因组技术和协调的专家咨询 用于提高基因组学和精准医学的精确性和可重复性。认识到日益增加的影响 MGBC已经建立了一个多药物的生物储存库， 耐药UTI分离株。这些服务和生物储存库是专门为满足以下两种需求而设计的： 研究项目的哥伦比亚奥布莱恩中心和机会池获奖者，并将提供给 更广泛的泌尿学研究社区。MGBC将通过以下目标实现这些目标： 将多药耐药UTI分离株的生物储存库扩展到纽约市的多个地点， 来自临床明确定义的具有不同UTI症状的患者的尿液生物储存器，并进行延长尿 用于微生物鉴定的培养物; 2）提供微生物组和宏基因组分析以及Hi-C/MetaPore-C 3）促进显性UTI致病性克隆的全基因组测序，以阐明细菌性UTI致病性克隆的基因组序列。 4）在多药耐药临床UTI分离株中产生细菌突变体 利用高效的CRISPR-Cas系统;以及6）为以下研究提供咨询和研究设计支持： 研究项目。重要的是，MGBC将作为其他乔治成员的国家资源， M.奥布莱恩合作研究中心和其他NIDDK泌尿学研究项目。密切合作 与行政核心一起，MGBC将确保遵守所有财政、行政和资源共享 施政纲要而MGBC还将为教育丰富和机会库的目标做出贡献 通过讲座，学生辅导和指导与微生物相关的实验设计的计划 机会池获奖者的基因组学。综上所述，哥伦比亚奥布莱恩U 54 MGBC将使国家- UTI中微生物的最新表征，重点是发展多药耐药性，通过提供 利用分子生物学、遗传学和组学技术的一套互补工具。

MICROBIAL GENOMICS BIOMEDICAL CORE (MGBC): PROJECT SUMMARY/ABSTRACT The mission of the Columbia University O’Brien Urology Research Center is to identify genetic factors and congenital malformations, such as vesicoureteral reflux, that predispose individuals to urinary tract infections (UTI) and to explore host-bacterial metabolic processes, such as heme pathways, that enable or prevent infection. UTI represent one of the most common infections, affecting 150 million people per year worldwide. In support of the goals of the Columbia O’Brien Urology Research Center the Microbial Genomics and Biomedical Core (MGBC) will provide high quality services for biobanking, extended bacterial culture, microbial genomics (microbiome analyses, comparative genomics), microbial genetics, consultation for study design and outreach for novel investigations into the pathogenesis of urinary tract infections. The MGBC will enable Columbia O’Brien Center investigators to have access to specialized genomic technologies and coordinated expert consultations for improved rigor and reproducibility in genomics and precision medicine. In recognition of the increasing impact of antimicrobial resistance in urinary tract infections the MGBC has established a biorepository of multi-drug resistant UTI isolates. The services and biorepository are specifically designed to meet the needs of two of the Research Projects of the Columbia O’Brien Center and Opportunity Pool Awardees and will be available to the wider urology research community. The MGBC will accomplish these goals through the following aims: 1) Expand a biorepository of multi-drug resistant UTI isolate to multiple sites across New York City, establish a urine biorepository from clinically well-defined patients with different UTI symptoms and perform extended urine culture for organism identification; 2) Provide Microbiome and metagenome analyses and Hi-C/MetaPore-C sequencing; 3) Facilitate whole genome sequencing of dominant UTI pathogenic clones to elucidate bacterial determinants of UTI symptomatology; 4) Generate bacterial mutants in multi-drug resistant clinical UTI isolates leveraging a highly efficient CRISPR-Cas system; and 6) Provide consultations and support of study design for the Research Projects. Importantly, the MGBC will serve as a national resource for members of other George M. O'Brien Cooperative Research Centers and other NIDDK Urologic Research Programs. In close collaboration with the Administrative Core the MGBC will ensure adherence to all fiscal, administrative, and resource sharing policies. The MGBC will also contribute to the goals of the Educational Enrichment and Opportunity Pool Programs through lectures, student mentorship, and guidance on experimental design related to microbial genomics for Opportunity Pool awardees. Taken together, the Columbia O’Brien U54 MGBC will enable state- of-the-art characterization of microbes in UTIs, with a focus on evolving multi-drug resistance, by providing a complementary set of tools harnessing molecular biology, genetics, and ‘omics technologies.